



JFW

PATENT

Our Docket: P-IMM 1003-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Robbins and Tritz

Serial No: 10/753,718

Filed: January 8, 2004

Title: RIBOZYME THERAPY FOR
THE TREATMENT OF
PROLIFERATIVE SKIN AND
EYE DISEASES

Commissioner for Patents
Alexandria, VA. 22313-1450

) Group Art Unit: 1614

) Examiner: Not known

) I hereby certify that this correspondence
) is being mailed first class to the United
) States Patent and Trademark Office on
) August 5, 2004.

David I. Spolter
David Spolter, Reg. No. 36,933

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. sec. 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449.

Also enclosed is a copy of the Form PTO-1449 filed in the parent case, U.S. ser. No. 09/696,791. Applicants hereby make the references listed on this form of record in the instant case. Copies of these references are available in the parent file.

No fees are deemed necessary in connection with the filing of this Information Disclosure Statement. However, if a fee is required, the Commissioner is hereby authorized to charge payment of such fee to Deposit Account No. 501559.

Respectfully submitted,

Date: August 5, 2004

David I. Spolter

David I. Spolter

Registration No. 36,933

Telephone: (732) 709-5117

LAW OFFICE OF DAVID SPOLTER
30 S. Adelaide Ave., #5M
Highland Park, NJ 08904
U.S.P.T.O. Customer No. 29447



| | | |
|--|---------------------------------|---------------------------|
| Form PTO 1449 US Department of Commerce Patent and Trademark Office | ATTY DOCKET NO: P-IMM 1003-2 | SERIAL NO.: 10/753,718 |
| | APPLICANTS: Robbins and Tritz | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | FILING DATE: January 8, 2004 | GROUP: 1614 |

U.S. PATENT DOCUMENTS

| EXAM. INITIALS | DOCUMENT NUMBER | DATE ISSUED | NAME | CLASS | SUB- CLASS | FILING DATE |
|-------------------|--------------------|----------------|------|-------|---------------|----------------|
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAM. INITIALS | DOCUMENT NUMBER | PUB. DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATIC (YES/NO) |
|-------------------|--------------------|--------------|---------|-------|---------------|------------------------|
| | WO 91 15580 | 17 Oct 1991 | | | | |
| | WO 99 50403 | 7 Oct 1999 | | | | |
| | WO 97 10334 | 20 Mar 1997 | | | | |
| | WO 00 32765 | 8 Jun 2000 | | | | |
| | WO 99 45920 | 16 Sep 1999 | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

| | | |
|----------|-----------------|--|
| | | |
| | | Mandava et al., Chimeric Ribozyme to Proliferating Cell Nuclear Antigen (PCNA) Prevents Retinal Detachment (RD) in a Model of Proliferative Vitroretinopathy (PVR), <u>Investigative Ophthalmology & Visual Science</u> , 41:2879 (15 Mar 2000). |
| | | Mandava et al., Ribozyme to Proliferating Cell Nuclear Antigen to Treat Proliferative Vitroretinopathy, <u>Investigative Ophthalmology & Visual Science</u> , 43:3338-48 (2002). |
| | | Ozaki et al., Intravitreal Sustained Release of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood-Retinal Barrier in Rabbits and Primates, <u>Exp Eye Res</u> , 64:505-17 (1997). |
| | | |
| | | |
| | | |
| EXAMINER | DATE CONSIDERED | |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

1/23/01
Date

Nathan K. Adderson
Nathan K. Adderson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Joan M. Robbins and Richard Tritz
Application No. : 09/696,791
Filed : October 25, 2000
For : RIBOZYME THERAPY FOR THE TREATMENT OF
PROLIFERATIVE SKIN AND EYE DISEASES

Art Unit : 1614
Docket No. : 480124.407

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT


Assistant Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

A handwritten signature in black ink, appearing to read "David W. Parker", written over a horizontal line.

David W. Parker

Registration No. 37,414

QXL:nka

Enclosures:

Postcard

Form PTO-1449

Cited References (16)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

Wpn\480124\407\IDS\idscoverletter.doc

FORM PTO-1449
(REV.7-80)

AUG 09 2004

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

480124.407

APPLICATION NO.

09/696,791

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Joan M. Robbins and Richard Tritz

FILING DATE

October 25, 2000

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|-----------------|----------|-------------------|-------|----------|-------------------------------|
| | AA | 6,132,967 | 10/17/00 | Grimm et al. | 435 | 6 | |
| | AB | 6,103,890 | 8/15/00 | Jarvis et al. | 536 | 24.5 | |
| | AC | 5,929,040 | 7/27/99 | Werther et al. | 514 | 44 | |
| | AD | 5,658,780 | 8/19/97 | Stinchcomb et al. | 235 | 366 | |
| | AE | 5,646,042 | 7/8/97 | Stinchcomb et al. | 435 | 366 | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION | |
|--|--|--------------------|------|---------|-------------|----|
| | | | | | YES | NO |
| | | | | | | |


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|----|---|
| | AF | Frimerman et al., "Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model," <i>Circulation</i> 99:697-703, February 9, 1999 |
| | AG | LaVail et al., "Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy," <i>Proceedings National Academy Science USA</i> 97(21): 11488-11493, October 10, 2000 |
| | AH | Flores-Aguilar et al., "Evaluation of Retinal Toxicity and Efficacy of Anti-Cytomegalovirus and Anti-Herpes Simplex Virus Antiviral Phosphorothioate Oligonucleotides ISIS 2922 and ISIS 4015," <i>The Journal of Infectious Diseases</i> 175: 1308-1316, June 1997 |
| | AI | Taylor et al., "Chimeric DNA-RNA hammerhead ribozymes have enhanced <i>in vitro</i> catalytic efficiency and increased stability <i>in vivo</i> ," <i>Nucleic Acids Research</i> 20(17):4559-4565, 1992 |
| | AJ | Morita et al., "Inhibition Of Rheumatoid Synovial Fibroblast Proliferation By Antisense Oligonucleotides Targeting Proliferating Cell Nuclear Antigen Messenger RNA," <i>Arthritis Rheumatism</i> 40(7):1292-1297, July 1997 |
| | AK | Gillardon et al., "Inhibition of c-Fos expression in the UV-irradiated epidermis by topical application of antisense oligodeoxynucleotides suppresses activation of proliferating cell nuclear antigen," <i>Carcinogenesis</i> 16(8): 1853-1856, 1995 |

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

| | | | | | | | | | |
|---|----|--|------|--|-----------------|---|-------------------------------|-------------------------------|--|
| FORM PTO-1449 (REV. 7-80) | |  | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 480124.407 | | APPLICATION NO. 09/696,791 | |
| INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i> | | | | | | APPLICANTS Joan M. Robbins and Richard Tritz | | | |
| | | | | | | FILING DATE October 25, 2000 | | GROUP ART UNIT 1614 | |
| U.S. PATENT DOCUMENTS | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | | |
| | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | | | TRANSLATION | | |
| | | | | | | | YES | NO | |
| | | | | | | | | | |
| OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i> | | | | | | | | | |
| | BA | Jaskulski et al., "Inhibition of Cellular Proliferation by Antisense Oligodeoxynucleotides to PCNA Cyclin," <i>Science</i> 240: 1544-1546, June 10, 1988 | | | | | | | |
| | BB | Capeans et al., "A <i>c-myc</i> Antisense Oligonucleotide Inhibits Human Retinal Pigment Epithelial Proliferation," <i>Exp. Eye Res.</i> 66: 581-589, 1998 | | | | | | | |
| | BC | O'Neill et al., "Ribozyme-Based Therapeutic Approaches for Autosomal Dominant Retinitis Pigmentosa," <i>Investigative Ophthalmology & Visual Science</i> 41(10): 2863-2869, September 2000 | | | | | | | |
| | BD | Probst, J., "Antisense Oligodeoxynucleotide and Ribozyme Design," <i>Methods</i> 22: 271-281, 2000 | | | | | | | |
| | BE | Kuang-Yu Jen and Alan M. Gewirtz, "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> 18: 307-319, 2000 | | | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | | | |
| * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s). | | | | | | | | | |